Cell Therapeutics' Pixuvri Could Be Stopped By Early Trial Termination
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee will consider whether the results for the non-Hodgkin's lymphoma treatment's Phase III trial, which suffered an unplanned early halt, are sufficient.
You may also be interested in...
Cell Therapeutics Should Consider Different Trial Design For Pixuvri, FDA's Pazdur Says
The odds were against Cell Therapeutics from the beginning of the Oncology Drugs Advisory Committee meeting, as FDA officials had concluded that the single, incomplete clinical trial did not provide enough evidence of efficacy.
Cell Therapeutics Should Consider Different Trial Design For Pixuvri, FDA's Pazdur Says
The odds were against Cell Therapeutics from the beginning of the Oncology Drugs Advisory Committee meeting, as FDA officials had concluded that the single, incomplete clinical trial did not provide enough evidence of efficacy.
Significance Of Evidence For Cell Therapeutics' Pixuvri Is On The Line
Delay in ODAC review - now rescheduled for March 22 - gave Cell Therapeutics time to respond to concerns raised in FDA's briefing material released in February.